FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Louis Weiner

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Physiology

Antibody-Dependent Cell Cytotoxicity

Anatomy

Tumor Cells, Cultured

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Jiping Zhang; Gregory P Adams; Hyung-Ok Lee; Wayne A Marasco; Stefanie R Mullins; Matthew K Robinson; Heidi Simmons; Matthildi Valianou; Louis M Weiner; Jonathan D Cheng
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
Igor A Astsaturov; Neal J Meropol; R Katherine Alpaugh; Barbara Burtness; Jonathan D Cheng; Sue McLaughlin; André Rogatko; Zhiheng Xu; James C Watson; Louis M Weiner; Steven J Cohen
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
Igor Astsaturov; Vladimir Ratushny; Anna Sukhanova; Margret B Einarson; Tetyana Bagnyukova; Yan Zhou; Karthik Devarajan; Joshua S Silverman; Nadezhda Tikhmyanova; Natalya Skobeleva; Anna Pecherskaya; Rochelle E Nasto; Catherine Sharma; Sandra A Jablonski; Ilya G Serebriiskii; Louis M Weiner; Erica A Golemis
Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Louis Weiner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jiping Zhang; Gregory P Adams; Hyung-Ok Lee; Wayne A Marasco; Stefanie R Mullins; Matthew K Robinson; Heidi Simmons; Matthildi Valianou; Louis M Weiner; Jonathan D Cheng
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2013;27(2):581-9.
2011: Igor A Astsaturov; Neal J Meropol; R Katherine Alpaugh; Barbara Burtness; Jonathan D Cheng; Sue McLaughlin; André Rogatko; Zhiheng Xu; James C Watson; Louis M Weiner; Steven J Cohen
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
American journal of clinical oncology 2011;34(1):70-5.
2010: Igor Astsaturov; Vladimir Ratushny; Anna Sukhanova; Margret B Einarson; Tetyana Bagnyukova; Yan Zhou; Karthik Devarajan; Joshua S Silverman; Nadezhda Tikhmyanova; Natalya Skobeleva; Anna Pecherskaya; Rochelle E Nasto; Catherine Sharma; Sandra A Jablonski; Ilya G Serebriiskii; Louis M Weiner; Erica A Golemis
Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.
Science signaling 2010;3(140):ra67.
2009: Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Mechanisms of tumor resistance to EGFR-targeted therapies.
Expert opinion on therapeutic targets 2009;13(3):339-62.
2008: Steven J Cohen; R Katherine Alpaugh; Irma Palazzo; Neal J Meropol; André Rogatko; Zhiheng Xu; John P Hoffman; Louis M Weiner; Jonathan D Cheng
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.
Pancreas 2008;37(2):154-8.
2008: Liat Binyamin; R Katherine Alpaugh; Tracey L Hughes; Charles T Lutz; Kerry S Campbell; Louis M Weiner
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(9):6392-401.
2008: Sandra Urtishak; R Katherine Alpaugh; Louis M Weiner; Ramona F Swaby
Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development.
Biomarkers in medicine 2008;2(2):137-45.
2008: Steven J Cohen; Paul F Engstrom; Nancy L Lewis; Corey J Langer; Susan McLaughlin; Mary Beard; Louis M Weiner; Neal J Meropol
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
American journal of clinical oncology 2008;31(1):1-5.
2007: Kalyani Narra; Stefanie R Mullins; Hyung-Ok Lee; Brenda Strzemkowski-Brun; Kimberly Magalong; Victoria J Christiansen; Patrick A McKee; Brian Egleston; Steven J Cohen; Louis M Weiner; Neal J Meropol; Jonathan D Cheng
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.
Cancer biology & therapy 2007;6(11):1691-9.
2007: David M Heimann; Louis M Weiner
Monoclonal antibodies in therapy of solid tumors.
Surgical oncology clinics of North America 2007;16(4):775-92, viii.
2007: Andre Konski; Jonathan D Cheng; Melvyn Goldberg; Tianyu Li; Alan Maurer; Jian Q Yu; Oleh Haluszka; Walter Scott; Neal J Meropol; Steven J Cohen; Gary Freedman; Louis M Weiner
Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
International journal of radiation oncology, biology, physics 2007;69(2):358-63.
2007: Louis M Weiner
Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer.
Nature reviews. Cancer 2007;7(9):701-6.
2007: Yong Tang; Jianlong Lou; R Katherine Alpaugh; Matthew K Robinson; James D Marks; Louis M Weiner
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(5):2815-23.
2007: Hossein Borghaei; R Katherine Alpaugh; Patricia Bernardo; Irma E Palazzo; Janice P Dutcher; Usha Venkatraj; William C Wood; Lori Goldstein; Louis M Weiner
Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(4):455-67.
2006: Benjamin Movsas; Hasmik Diratzouian; Alexandra Hanlon; Harry Cooper; Gary Freedman; Andre Konski; Elin R Sigurdson; John Hoffman; Neal J Meropol; Louis M Weiner; Lawrence R Coia; Rachelle Lanciano; Joanne Stein; Debra Kister; Burton L Eisenberg
Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer.
American journal of clinical oncology 2006;29(5):435-41.
2006: Steven J Cohen; R Katherine Alpaugh; Steve Gross; S Mark O'Hara; Denis A Smirnov; Leon W M M Terstappen; W Jeffrey Allard; Maryann Bilbee; Jonathan D Cheng; John P Hoffman; Nancy L Lewis; Ann Pellegrino; André Rogatko; Elin R Sigurdson; Hao Wang; James C Watson; Louis M Weiner; Neal J Meropol
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer.
Clinical colorectal cancer 2006;6(2):125-32.
2006: Gregory P Adams; Mei-Sheng Tai; John E McCartney; James D Marks; Walter F Stafford; L L Houston; James S Huston; Louis M Weiner
Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(5):1599-605.
2006: Leonard R Henry; Melvyn Goldberg; Walter Scott; Andre Konski; Neal J Meropol; Gary Freedman; Louis M Weiner; Perry Watts; Mary Beard; Susan McLaughlin; Jonathan D Cheng
Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report.
Annals of surgical oncology 2006;13(2):214-20.
2006: Louis M Weiner; Hossein Borghaei
Targeted therapies in solid tumors: monoclonal antibodies and small molecules.
Human antibodies 2006;15(3):103-11.
2006: Louis M Weiner
Fully human therapeutic monoclonal antibodies.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(1):1-9.
2005: Eva M Horak; Tara Heitner; Matthew K Robinson; Heidi H Simmons; Jennifer Garrison; Maria Russeva; Polina Furmanova; Jianlong Lou; Yu Zhou; Qing-An Yuan; Louis M Weiner; Gregory P Adams; James D Marks
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
Cancer biotherapy & radiopharmaceuticals 2005;20(6):603-13.
2005: Lorraine C Snyder; Igor Astsaturov; Louis M Weiner
Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
Clinical colorectal cancer 2005;5 Suppl 2():S71-80.
2005: Gregory P Adams; Louis M Weiner
Monoclonal antibody therapy of cancer.
Nature biotechnology 2005;23(9):1147-57.
2005: Denis A Smirnov; Daniel R Zweitzig; Bradley W Foulk; M Craig Miller; Gerald V Doyle; Kenneth Pienta; Neal J Meropol; Louis M Weiner; Steven J Cohen; Jose G Moreno; Mark C Connelly; Leon W M M Terstappen; S Mark O'Hara
Global gene expression profiling of circulating tumor cells.
Cancer research 2005;65(12):4993-7.
2005: Jonathan D Cheng; Matthildi Valianou; Adrian A Canutescu; Eileen K Jaffe; Hyung-Ok Lee; Hao Wang; Jack H Lai; William W Bachovchin; Louis M Weiner
Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth.
Molecular cancer therapeutics 2005;4(3):351-60.
2004: Lillian S Shahied; Yong Tang; R Katherine Alpaugh; Robert Somer; Dana Greenspon; Louis M Weiner
Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
The Journal of biological chemistry 2004;279(52):53907-14.
2004: Gregory P Adams; Calvin Shaller; Ekaterina Dadachova; Heidi H Simmons; Eva M Horak; Abohawariat Tesfaye; Andres J P Klein-Szanto; James D Marks; Martin W Brechbiel; Louis M Weiner
A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.
Cancer research 2004;64(17):6200-6.
2004: Steven J Cohen; James Gallo; Nancy L Lewis; R Katherine Alpaugh; Louis Gentner; André Rogatko; Gwen Yeslow; Jessie Schol; Tom Verhaeghe; Peter Zannikos; Peter A Palmer; Louis M Weiner; Neal J Meropol
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2004;53(6):513-8.
2004: Jonathan D Cheng; James S Babb; Corey Langer; Steinar Aamdal; Francisco Robert; Lars Rupert Engelhardt; Olov Fernberg; Joan Schiller; Goran Forsberg; R Katherine Alpaugh; Louis M Weiner; André Rogatko
Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(4):602-9.
2003: Melvyn Goldberg; Jeffrey Farma; Craig Lampert; Patrick Colarusso; Lawrence R Coia; Harold Frucht; Eric Goosenberg; Mary Beard; Louis M Weiner
Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report.
The Journal of thoracic and cardiovascular surgery 2003;126(4):1168-73.
2003: Jonathan D Cheng; Louis M Weiner
Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647, 2003.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1590-5.
2003: Steven J Cohen; Linus Ho; Sulabha Ranganathan; James L Abbruzzese; R Katherine Alpaugh; Mary Beard; Nancy L Lewis; Susan McLaughlin; André Rogatko; Juan Jose Perez-Ruixo; Amanda M Thistle; Tom Verhaeghe; Hao Wang; Louis M Weiner; John J Wright; Gary R Hudes; Neal J Meropol
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(7):1301-6.
2003: Margaret von Mehren; Gregory P Adams; Louis M Weiner
Monoclonal antibody therapy for cancer.
Annual review of medicine 2003;54():343-69.
2002: Nancy L Lewis; Richard Scher; James M Gallo; Paul F Engstrom; Christine E Szarka; Samuel Litwin; Andrea L Adams; Deborah Kilpatrick; Diane Brady; Louis M Weiner; Neal J Meropol
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Cancer chemotherapy and pharmacology 2002;50(4):257-65.
2002: Jonathan D Cheng; Roland L Dunbrack; Matthildi Valianou; André Rogatko; R Katherine Alpaugh; Louis M Weiner
Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model.
Cancer research 2002;62(16):4767-72.
2002: Louis M Weiner
Beyond neutrophil recovery: manipulation of the tumor microenvironment by GM-CSF to control cancer.
Oncology (Williston Park, N.Y.) 2002;16(1 Suppl 1):7-9.
2001: Gregory P Adams; R Schier; AM McCall; Heidi H Simmons; Eva M Horak; R Katherine Alpaugh; James D Marks; Louis M Weiner
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
Cancer research 2001;61(12):4750-5.
2001: AM McCall; L Shahied; AR Amoroso; Eva M Horak; Heidi H Simmons; U Nielson; Gregory P Adams; R Schier; James D Marks; Louis M Weiner
Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(10):6112-7.
2001: Margaret von Mehren; Philip M Arlen; James L Gulley; André Rogatko; Harry S Cooper; Neal J Meropol; R Katherine Alpaugh; M Davey; Susan McLaughlin; Mary Beard; Kwong-Yok Tsang; J Schlom; Louis M Weiner
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1181-91.
2001: D B Powers; Peter Amersdorfer; Marie-Alix Poul; Ulrik B Nielsen; M R Shalaby; Gregory P Adams; Louis M Weiner; James D Marks
Expression of single-chain Fv-Fc fusions in Pichia pastoris.
Journal of immunological methods 2001;251(1-2):123-35.
2001: Russell J Schilder; James M Gallo; Michael Millenson; Michael A Bookman; Louis M Weiner; André Rogatko; B Rogers; K Padavic-Shallers; MP Boente; Norman G Rosenblum; Andrea L Adams; S Ciccotto; Robert F Ozols
Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1183-94.
2000: Louis M Weiner; Gregory P Adams
New approaches to antibody therapy.
Oncogene 2000;19(53):6144-51.
2000: Ulrik B Nielsen; Gregory P Adams; Louis M Weiner; James D Marks
Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Cancer research 2000;60(22):6434-40.
2000: J D Cheng; P T Rieger; Margaret von Mehren; Gregory P Adams; Louis M Weiner
Recent advances in immunotherapy and monoclonal antibody treatment of cancer.
Seminars in oncology nursing 2000;16(4 Suppl 1):2-12.
2000: Gary R Hudes; Christine E Szarka; A Adams; S Ranganathan; R A McCauley; Louis M Weiner; Corey J Langer; Samuel Litwin; Gwen Yeslow; T Halberr; M Qian; James M Gallo
Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3071-80.
2000: Margaret von Mehren; Philip M Arlen; Kwong-Yok Tsang; André Rogatko; Neal J Meropol; Harry S Cooper; M Davey; Susan McLaughlin; J Schlom; Louis M Weiner
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(6):2219-28.
2000: Gregory P Adams; Calvin Shaller; L L Chappell; Carl Wu; Eva M Horak; Heidi H Simmons; S Litwin; James D Marks; Louis M Weiner; Martin W Brechbiel
Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules.
Nuclear medicine and biology 2000;27(4):339-46.
2000: Louis M Weiner
Bispecific antibodies in cancer therapy.
Cancer journal (Sudbury, Mass.) 2000;6 Suppl 3():S265-71.
2000: Susan J Knox; Michael L Goris; Margaret A Tempero; Paul L Weiden; L Gentner; Hazel Breitz; Gregory P Adams; Axworthy Don; S Gaffigan; K Bryan; Darrell R Fisher; David Colcher; I D Horak; Louis M Weiner
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):406-14.
1999: AR Amoroso; R Katherine Alpaugh; M W Barth; AM McCall; Louis M Weiner
Production and characterization of mice transgenic for the A and B isoforms of human FcgammaRIII.
Cancer immunology, immunotherapy : CII 1999;48(8):443-55.
1999: Louis M Weiner
Monoclonal antibody therapy of cancer.
Seminars in oncology 1999;26(5 Suppl 14):43-51.
1999: Louis M Weiner
An overview of monoclonal antibody therapy of cancer.
Seminars in oncology 1999;26(4 Suppl 12):41-50.
1999: AM McCall; Gregory P Adams; AR Amoroso; Ulrik B Nielsen; L Zhang; Eva M Horak; Heidi H Simmons; R Schier; James D Marks; Louis M Weiner
Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
Molecular immunology 1999;36(7):433-45.
1999: Louis M Weiner
Paclitaxel in the treatment of esophageal cancer.
Seminars in oncology 1999;26(1 Suppl 2):106-8.
1998: Steven M Keller; L M Ryan; Lawrence R Coia; P Dang; D J Vaught; C Diggs; Louis M Weiner; A B Benson
High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction: results of a phase II study of the Eastern Cooperative Oncology Group.
Cancer 1998;83(9):1908-16.
1998: R Katherine Alpaugh; Margaret von Mehren; I Palazzo; M B Atkins; Joseph A Sparano; L Schuchter; Louis M Weiner; Janice P Dutcher
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon.
Medical oncology (Northwood, London, England) 1998;15(3):191-8.
1998: Benjamin Movsas; Alexandra L Hanlon; Rachelle Lanciano; R M Scher; Louis M Weiner; Elin R Sigurdson; John P Hoffman; Burton L Eisenberg; Harry S Cooper; S Provins; Lawrence R Coia
Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.
International journal of radiation oncology, biology, physics 1998;42(1):43-50.
1998: R Katherine Alpaugh; J Schultz; Cecilia McAleer; Bruce Giantonio; Robert Persson; M Burnite; S E Nielsen; L Vitek; B Persson; Louis M Weiner
Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1903-14.
1998: AM McCall; AR Amoroso; C Sautès; James D Marks; Louis M Weiner
Characterization of anti-mouse Fc gamma RII single-chain Fv fragments derived from human phage display libraries.
Immunotechnology : an international journal of immunological engineering 1998;4(1):71-87.
1998: Gregory P Adams; R Schier; AM McCall; Robert Crawford; E J Wolf; Louis M Weiner; James D Marks
Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
British journal of cancer 1998;77(9):1405-12.
1998: Gregory P Adams; R Schier; K Marshall; E J Wolf; AM McCall; James D Marks; Louis M Weiner
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
Cancer research 1998;58(3):485-90.
1997: Louis M Weiner; Patrick Colarusso; Melvyn Goldberg; Carolyn Dresler; Lawrence R Coia
Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Seminars in oncology 1997;24(6 Suppl 19):S19-93-S19-95.
1997: Louis M Weiner; R Katherine Alpaugh; Margaret von Mehren
Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins.
Cancer immunology, immunotherapy : CII 1997;45(3-4):190-2.
1997: Louis M Weiner
Biological therapies for gastrointestinal cancers.
Current opinion in oncology 1997;9(4):373-9.
1997: J I Clark; R Katherine Alpaugh; Margaret von Mehren; J Schultz; Julie R Gralow; Martin A Cheever; D B Ring; Louis M Weiner
Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
Cancer immunology, immunotherapy : CII 1997;44(5):265-72.
1997: Bruce Giantonio; R Katherine Alpaugh; J Schultz; Cecilia McAleer; Duane W Newton; B Shannon; Y Guedez; Malak Kotb; L Vitek; Robert Persson; Per Olov Gunnarsson; T Kalland; M Dohlsten; B Persson; Louis M Weiner
Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1994-2007.
1996: R Schier; AM McCall; Gregory P Adams; K W Marshall; H Merritt; M Yim; Robert Crawford; Louis M Weiner; C Marks; James D Marks
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
Journal of molecular biology 1996;263(4):551-67.
1996: Margaret von Mehren; Louis M Weiner
Monoclonal antibody-based therapy.
Current opinion in oncology 1996;8(6):493-8.
1996: J S Huston; Andrew J T George; Gregory P Adams; W F Stafford; François Jamar; M S Tai; J E McCartney; H Oppermann; B T Heelan; A Michael Peters; L L Houston; M A Bookman; E J Wolf; Louis M Weiner
Single-chain Fv radioimmunotargeting.
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 1996;40(3):320-33.
1996: David H Munn; A G Bree; A C Beall; M D Kaviani; H Sabio; R G Schaub; R Katherine Alpaugh; Louis M Weiner; Samuel J Goldman
Recombinant human macrophage colony-stimulating factor in nonhuman primates: selective expansion of a CD16+ monocyte subset with phenotypic similarity to primate natural killer cells.
Blood 1996;88(4):1215-24.
1996: Louis M Weiner; R Katherine Alpaugh; AR Amoroso; Gregory P Adams; D B Ring; M W Barth
Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII.
Cancer immunology, immunotherapy : CII 1996;42(3):141-50.
1996: R Schier; J Bye; G Apell; AM McCall; Gregory P Adams; M Malmqvist; Louis M Weiner; James D Marks
Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.
Journal of molecular biology 1996;255(1):28-43.
1996: AR Amoroso; J I Clark; Samuel Litwin; S Hsieh-Ma; T Shi; R Katherine Alpaugh; Gregory P Adams; E J Wolf; D B Ring; Louis M Weiner
Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor.
Cancer research 1996;56(1):113-20.
1995: Gregory P Adams; J E McCartney; E J Wolf; J Eisenberg; J S Huston; M A Bookman; P Moldofsky; W F Stafford; L L Houston; Louis M Weiner
Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1995;36(12):2276-81.
1995: Louis M Weiner; J I Clark; M Davey; W S Li; I Garcia de Palazzo; D B Ring; R Katherine Alpaugh
Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Cancer research 1995;55(20):4586-93.
1995: Louis M Weiner; J I Clark; D B Ring; R Katherine Alpaugh
Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Journal of hematotherapy 1995;4(5):453-6.
1995: Andrew J T George; François Jamar; M S Tai; B T Heelan; Gregory P Adams; J E McCartney; L L Houston; Louis M Weiner; H Oppermann; A Michael Peters
Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(18):8358-62.
1995: J I Clark; Louis M Weiner
Biologic treatment of human cancer.
Current problems in cancer 1995;19(4):185-262.
1995: O Algan; Lawrence R Coia; Steven M Keller; P F Engstrom; Louis M Weiner; Timothy Schultheiss; Gerald E Hanks
Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy: results of sequential nonrandomized phase II studies.
International journal of radiation oncology, biology, physics 1995;32(3):753-61.
1995: Mansoor N Saleh; Samuel J Goldman; Albert F LoBuglio; A C Beall; H Sabio; M C McCord; L Minasian; R Katherine Alpaugh; Louis M Weiner; David H Munn
CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor.
Blood 1995;85(10):2910-7.
1995: R Schier; James D Marks; E J Wolf; G Apell; Cindy Wong; J E McCartney; M A Bookman; J S Huston; L L Houston; Louis M Weiner
In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library.
Immunotechnology : an international journal of immunological engineering 1995;1(1):73-81.
1995: Gregory P Adams; J E McCartney; E J Wolf; J Eisenberg; M S Tai; J S Huston; W F Stafford; M A Bookman; L L Houston; Louis M Weiner
Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration.
Cancer immunology, immunotherapy : CII 1995;40(5):299-306.
1995: R L Krigel; K Padavic-Shaller; C Toomey; R L Comis; Louis M Weiner
Phase I study of sequentially administered recombinant tumor necrosis factor and recombinant interleukin-2.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;17(3):161-70.
1995: J E McCartney; M S Tai; R M Hudziak; Gregory P Adams; Louis M Weiner; D Jin; W F Stafford; S Liu; M A Bookman; A A Laminet
Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides.
Protein engineering 1995;8(3):301-14.
1995: N B Haas; Russell J Schilder; S Nash; Louis M Weiner; R C Catalano; Robert F Ozols; Peter J O'Dwyer
A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer.
Investigational new drugs 1995;13(3):229-33.
1995: Corey J Langer; R Catalano; Louis M Weiner; R Scher; P Bagchi; B Saren; R L Comis
Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.
Cancer investigation 1995;13(2):150-9.
1994: Louis M Weiner; W Li; M Holmes; R B Catalano; M Dovnarsky; K Padavic; R Katherine Alpaugh
Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
Cancer research 1994;54(15):4084-90.
1994: I Redei; F Green; John P Hoffman; Louis M Weiner; R Scher; Peter J O'Dwyer
Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
Investigational new drugs 1994;12(4):319-21.
1993: I Garcia de Palazzo; A Klein-Szanto; Louis M Weiner
Immunohistochemical detection of c-erbB-2 expression by neoplastic human tissue using monospecific and bispecific monoclonal antibodies.
The International journal of biological markers 1993;8(4):233-9.
1993: Louis M Weiner; M Holmes; A Richeson; A Godwin; Gregory P Adams; S T Hsieh-Ma; D B Ring; R Katherine Alpaugh
Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(5):2877-86.
1993: Gregory P Adams; J E McCartney; M S Tai; H Oppermann; J S Huston; W F Stafford; M A Bookman; I Fand; L L Houston; Louis M Weiner
Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv.
Cancer research 1993;53(17):4026-34.
1993: I E Garcia de Palazzo; Gregory P Adams; P Sundareshan; Albert J Wong; Joseph R Testa; D D Bigner; Louis M Weiner
Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas.
Cancer research 1993;53(14):3217-20.
1993: Louis M Weiner; E Harvey; K Padavic-Shaller; J K Willson; C Walsh; F LaCreta; M B Khazaeli; J M Kirkwood; D G Haller
Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(2):110-6.
1993: Louis M Weiner; Gary R Hudes; J Kitson; J Walczak; P Watts; Samuel Litwin; Peter J O'Dwyer
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
Cancer immunology, immunotherapy : CII 1993;36(3):185-90.
1993: Louis M Weiner; M Holmes; Gregory P Adams; F LaCreta; P Watts; I Garcia de Palazzo
A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Cancer research 1993;53(1):94-100.
1992: I Garcia de Palazzo; M Holmes; Cicek Gercel-Taylor; Louis M Weiner
Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
Cancer research 1992;52(20):5713-9.
1992: I G de Palazzo; J Kitson; Cicek Gercel-Taylor; S Adams; Louis M Weiner
Bispecific monoclonal antibody regulation of Fc gamma RIII-directed tumor cytotoxicity by large granular lymphocytes.
Cellular immunology 1992;142(2):338-47.
1991: Louis M Weiner; K Padavic-Shaller; J Kitson; P Watts; R L Krigel; Samuel Litwin
Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Cancer research 1991;51(15):3910-8.
1991: R L Krigel; K A Padavic-Shaller; A A Rudolph; J D Young; Louis M Weiner; M Konrad; R L Comis
Hemorrhagic gastritis as a new dose-limiting toxicity of recombinant tumor necrosis factor.
Journal of the National Cancer Institute 1991;83(2):129-31.
1990: I G de Palazzo; Cicek Gercel-Taylor; J Kitson; Louis M Weiner
Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
Cancer research 1990;50(22):7123-8.
1990: Peter J O'Dwyer; A R Paul; J Walczak; Louis M Weiner; Samuel Litwin; R L Comis
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(9):1497-503.
1989: Louis M Weiner; J O'Dwyer; J Kitson; R L Comis; A E Frankel; R J Bauer; M S Konrad; E S Groves
Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.
Cancer research 1989;49(14):4062-7.
1989: Louis M Weiner; C M Zarou; J O'Brien; D Ring
Effector characteristics of the IgG3 murine monoclonal antibody 113F1.
Journal of biological response modifiers 1989;8(3):227-37.
1988: Louis M Weiner; P J Moldofsky; RA Gatenby; J O'Dwyer; J O'Brien; Samuel Litwin; R L Comis
Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Cancer research 1988;48(9):2568-73.
1988: RA Gatenby; P J Moldofsky; Louis M Weiner
Metastatic colon cancer: correlation of oxygen levels with I-131 F(ab')2 uptake.
Radiology 1988;166(3):757-9.
1988: Louis M Weiner; Z Steplewski; H Koprowski; Samuel Litwin; R L Comis
Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes.
Cancer research 1988;48(4):1042-6.